[Form 4] Bio-Rad Laboratories, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Bio-Rad Laboratories (BIO) Form 4: Courtney C. Enloe, EVP, General Counsel & Secretary, reported restricted stock units vesting and a small open-market sale. On 09/05/2025, 2,740 RSUs vested and were converted into shares; this increased reported holdings to 903.991 shares (which includes 6.5980 shares from the employee stock purchase plan). On 09/06/2025 an additional 768 RSUs were reported as acquired/vested. Also on 09/06/2025 the filing shows a disposition of 275 shares sold at $295.43 each, leaving 628.991 shares beneficially owned after the sale. The RSUs vest over four years at 25% per year.

Insights

Securities Analyst

TL;DR: Routine executive equity vesting with a limited open-market sale; appears immaterial to company capital structure.

The filing documents standard compensation settlement through vesting of restricted stock units totaling 2,740 shares on 09/05/2025 and an additional 768-unit recognition on 09/06/2025, consistent with time-based vesting (25% annually). The disclosure also shows a sale of 275 shares at $295.43 on 09/06/2025. Post-transaction beneficial ownership declined from 903.991 to 628.991 shares, reflecting the sale. These transactions are typical for executive compensation realization and do not indicate new grants, large-scale disposals, or changes to outstanding share count disclosed here.

Corporate Governance Expert

TL;DR: Compliance-focused Form 4 showing vesting and a reported sale; no governance red flags in the disclosure.

The report identifies Courtney C. Enloe as an officer and reports vesting mechanics: each RSU equals one share and vests 25% per year. The filing includes an explanatory note that 6.5980 shares were acquired under the ESPP on 06/30/2025. Signature and filing formalities are present. From a governance perspective, the form meets Section 16 reporting requirements and provides the necessary transaction codes and holdings updates without material omissions in the disclosed fields.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ENLOE COURTNEY C

(Last) (First) (Middle)

C/O BIO-RAD LABORATORIES, INC.

1000 ALFRED NOBEL DRIVE

(Street)

HERCULES CA 94547

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIO-RAD LABORATORIES, INC. [ BIO BIO.B ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, General Counsel & Sec

3. Date of Earliest Transaction (Month/Day/Year)
09/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Bio-Rad A Common Stock	09/06/2025		M		768(1)	A	$0	903.991(2)	D
Bio-Rad A Common Stock	09/06/2025		F		275	D	$295.43	628.991	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0(3)	09/05/2025		A		2,740		(4)	(4)	Bio-Rad A Common Stock	2,740	$0	2,740	D
Restricted Stock Units	$0(3)	09/06/2025		M			768	(4)	(4)	Bio-Rad A Common Stock	768	$0	2,304	D

Explanation of Responses:

1. Shares of Class A common stock acquired on the vesting of restricted stock units.

2. Includes 6.5980 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 06/30/2025.

3. Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.

4. The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.

Remarks:

	/s/ Courtney C. Enloe	09/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.